← All trials
NCT00029380
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 1999
- Primary completion
- Aug 1, 2006
- Completion date
- Aug 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- University of California, San FranciscoStudy chair
- Thomas Jefferson UniversityStudy chair
- University of PennsylvaniaStudy chair
- Children's National Medical CenterStudy chair
- Hopital Ste-JustineStudy chair
- Texas Transplant InstituteStudy chair
- Duke UniversityStudy chair
- University of MiamiStudy chair
- Louisiana State UniversityStudy chair
- Northwestern UniversityStudy chair
- Rutgers UniversityStudy chair
- The University of Texas, DallasStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.